BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 26669253)

  • 1. Frontline treatment of epithelial ovarian cancer.
    Goh J; Mohan GR; Ladwa R; Ananda S; Cohen PA; Baron-Hay S
    Asia Pac J Clin Oncol; 2015 Dec; 11 Suppl 6():1-16. PubMed ID: 26669253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
    Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
    Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variation and prognostic value of serum plasminogen activator inhibitor-1 before and after chemotherapy in patients with epithelial ovarian cancer.
    Chen S; Tai H; Tong X; Wang J; Yang F; Yang Y; Yiqin O
    J Obstet Gynaecol Res; 2014 Sep; 40(9):2058-65. PubMed ID: 25181626
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical management of epithelial ovarian cancer during pregnancy.
    Grimm D; Woelber L; Trillsch F; Keller-v Amsberg G; Mahner S
    Eur J Cancer; 2014 Mar; 50(5):963-71. PubMed ID: 24462638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of cytoreductive surgery and HIPEC in epithelial ovarian cancer.
    Halkia E; Spiliotis J
    J BUON; 2015 May; 20 Suppl 1():S12-28. PubMed ID: 26051328
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
    Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
    Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Glasgow Prognostic Score (GPS) is a novel prognostic indicator in advanced epithelial ovarian cancer: a multicenter retrospective study.
    Zhu J; Wang H; Liu CC; Lu Y; Tang H
    J Cancer Res Clin Oncol; 2016 Nov; 142(11):2339-45. PubMed ID: 27566683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.
    Nagaraj AB; Joseph P; DiFeo A
    Biomark Med; 2015; 9(3):241-57. PubMed ID: 25731210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Epithelial ovarian cancer - a change of paradigm].
    Heinzelmann-Schwarz V
    Ther Umsch; 2011 Oct; 68(10):565-72. PubMed ID: 21968896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective analysis of outcomes of secondary debulking surgery for recurrent epithelial ovarian cancer with favorable prognostic factors.
    Nasu K; Kai K; Hirakawa T; Nishida M; Matsumoto H; Kawano Y; Narahara H
    J Obstet Gynaecol Res; 2014 Mar; 40(3):791-6. PubMed ID: 24245582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.
    Deraco M; Kusamura S; Virzì S; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Iusco DR; Baratti D
    Gynecol Oncol; 2011 Aug; 122(2):215-20. PubMed ID: 21665254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients.
    Bakrin N; Cotte E; Golfier F; Gilly FN; Freyer G; Helm W; Glehen O; Bereder JM
    Ann Surg Oncol; 2012 Dec; 19(13):4052-8. PubMed ID: 22825772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quantitative metabolic parameters measured on F-18 FDG PET/CT predict survival after relapse in patients with relapsed epithelial ovarian cancer.
    Kim CY; Jeong SY; Chong GO; Son SH; Jung JH; Kim DH; Lee SW; Ahn BC; Lee J
    Gynecol Oncol; 2015 Mar; 136(3):498-504. PubMed ID: 25557270
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic factors for maximally or optimally cytoreduced stage III nonserous epithelial ovarian carcinoma treated with carboplatin/paclitaxel chemotherapy.
    Cuylan ZF; Meydanli MM; Sari ME; Akbayir O; Celik H; Dede M; Sahin H; Gungorduk K; Kuscu E; Ozgul N; Gungor T; Ayhan A
    J Obstet Gynaecol Res; 2018 Jul; 44(7):1284-1293. PubMed ID: 29727055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study.
    Deraco M; Virzì S; Iusco DR; Puccio F; Macrì A; Famulari C; Solazzo M; Bonomi S; Grassi A; Baratti D; Kusamura S
    BJOG; 2012 Jun; 119(7):800-9. PubMed ID: 22571746
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant chemotherapy for advanced epithelial ovarian cancer.
    Hall TR; Dizon DS
    Clin Adv Hematol Oncol; 2016 Apr; 14(4):262-8. PubMed ID: 27166608
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic and predictive value of CA-125 in the primary treatment of epithelial ovarian cancer: potentials and pitfalls.
    Díaz-Padilla I; Razak AR; Minig L; Bernardini MQ; María Del Campo J
    Clin Transl Oncol; 2012 Jan; 14(1):15-20. PubMed ID: 22262714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and clinical management of 275 patients with advanced ovarian cancer International Federation of Obstetrics and Gynecology II to IV inside the European Ovarian Cancer Translational Research Consortium-OVCAD.
    Chekerov R; Braicu I; Castillo-Tong DC; Richter R; Cadron I; Mahner S; Woelber L; Marth C; Van Gorp T; Speiser P; Zeillinger R; Vergote I; Sehouli J
    Int J Gynecol Cancer; 2013 Feb; 23(2):268-75. PubMed ID: 23358178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Does neoadjuvant chemotherapy plus cytoreductive surgery improve survival rates in patients with advanced epithelial ovarian cancer compared with cytoreductive surgery alone?
    Solmaz U; Mat E; Dereli ML; Turan V; Peker N; Tosun G; Dogan A; Adiyeke M; Ozdemir A; Gungorduk K; Sanci M; Yildirim Y
    J BUON; 2015; 20(3):847-54. PubMed ID: 26214639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clear cell carcinoma of the ovary: a review of the literature.
    del Carmen MG; Birrer M; Schorge JO
    Gynecol Oncol; 2012 Sep; 126(3):481-90. PubMed ID: 22525820
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.